MDGL (Madrigal Pharmaceuticals) GF Score: 31/100 (As of Jun. 25, 2026) — 14% Below Median


MDGL Madrigal Pharmaceuticals Inc MDGL
31 GF Score
Price $512.33
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals GF Score?

Madrigal Pharmaceuticals MDGL +0.50% 31 GF Score is 31 as of Jun. 25, 2026, which is 14% below its 10-year median of 36.00. GuruFocus rates MDGL with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Madrigal Pharmaceuticals has the GF Score of 31, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 10/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Madrigal Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Madrigal Pharmaceuticals  (NAS:MDGL) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Madrigal Pharmaceuticals GF Score Related Terms

MDGL vs BMRN, ARWR, AXSM: GF Score Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Madrigal Pharmaceuticals GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's GF Score falls into.


MDGL
31GF Score
Madrigal Pharmaceuticals Inc MDGL
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 31 mean?
Madrigal Pharmaceuticals (MDGL) has a GF Score of 31 as of Jun. 25, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Madrigal Pharmaceuticals and its competitors. This is 14% below median its historical median of 36.00. Over the past decade, Madrigal Pharmaceuticals' GF Score has ranged from 20.00 to 44.00.
Is Madrigal Pharmaceuticals' GF Score too high?
Madrigal Pharmaceuticals' current GF Score of 31 is 14% below median its 10-year median of 36.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 44.00. Overall, Madrigal Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' GF Score compare to BMRN and ARWR?
Madrigal Pharmaceuticals' GF Score of 31 can be compared against companies in the Biotechnology industry. Historically, Madrigal Pharmaceuticals' own GF Score has ranged from 20.00 to 44.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current GF Score is 31, which is 14% below median its own 10-year median of 36.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MDGL) has a current GF Score of 31. The current GF Score is 31, which is 14% below median its 10-year median of 36.00. Madrigal Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MDGL), the current GF Score is 31 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
31GF Score

Get the complete analysis for MDGL

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$512.33
Price